Answers are grounded in this paper and cite their sources.
Explores the role of myeloid FABP5 in inflammatory pain modulation, indicating potential therapeutic targets.
The initiation and maintenance of pain involves complex neuroimmune interactions, with myeloid cell output finetuning the balance between pronociceptive and antinociceptive signaling. Fatty acid binding protein 5 (FABP5) is a lipid chaperone whose inhibition produces antinociceptive effects in models of inflammatory pain. While FABP5 is highly expressed in myeloid cells that are recruited to sites of inflammation, the contribution of myeloid FABP5 to nociception is unknown. Utilizing myeloid-specific FABP5 conditional knockout (cKO) mice, we demonstrate that FABP5 + myeloid cells infiltrate into the paw following the onset of carrageenan-induced inflammation. However, myeloid cell recruitment was unaffected by FABP5 deletion. FABP5 cKO were characterized by attenuated development of inflammatory thermal hyperalgesia, which was observed throughout the experimental time course and was evident in both sexes. Transcriptomic profiling of myeloid cells obtained from carrageenan injected paws identified numerous differentially expressed genes between FABP5 cKO mice and Flox controls. Notably, FABP5 cKO myeloid cells featured elevated expression of interleukin-10 (IL-10) and CD206, indicative of polarization towards an M2-like anti-inflammatory state. Collectively, this study ascribes a new role to myeloid FABP5 in pain modulation, thereby expanding the repertoire of cell-types wherein FABP5 regulates nociception to myeloid cells.
No takes yet. Share an insight, caveat, or question.
Doswell et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: